{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T22:53:16Z","timestamp":1754261596335,"version":"3.37.3"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["704735"],"award-info":[{"award-number":["704735"]}],"id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","award":["17644"],"award-info":[{"award-number":["17644"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s10552-022-01570-1","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:04:01Z","timestamp":1647893041000},"page":"801-812","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-hypertensive medications and risk of colorectal cancer: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4100-5302","authenticated-orcid":false,"given":"Jia","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruona","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parveen","family":"Bhatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Spinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4383-5641","authenticated-orcid":false,"given":"Rachel A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"1570_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills KT, Stefanescu A, He J (2020) The global epidemiology of hypertension. Nat Rev Nephrol 16:223\u2013237. https:\/\/doi.org\/10.1038\/s41581-019-0244-2","journal-title":"Nat Rev Nephrol"},{"key":"1570_CR2","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.cjca.2018.02.022","volume":"34","author":"KA Nerenberg","year":"2018","unstructured":"Nerenberg KA, Zarnke KB, Leung AA et al (2018) Hypertension Canada\u2019s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol 34:506\u2013525. https:\/\/doi.org\/10.1016\/j.cjca.2018.02.022","journal-title":"Can J Cardiol"},{"key":"1570_CR3","doi-asserted-by":"publisher","first-page":"62545","DOI":"10.18632\/oncotarget.19117","volume":"8","author":"H Ni","year":"2017","unstructured":"Ni H, Rui Q, Zhu X, Yu Z, Gao R, Liu H (2017) Antihypertensive drug use and breast cancer risk: a meta-analysis of observational studies. Oncotarget 8:62545","journal-title":"Oncotarget"},{"key":"1570_CR4","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/pds.1656","volume":"17","author":"TL Assimes","year":"2008","unstructured":"Assimes TL, Elstein E, Langleben A, Suissa S (2008) Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf 17:1039\u20131049. https:\/\/doi.org\/10.1002\/pds.1656","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1570_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1570_CR6","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1053\/j.gastro.2019.06.043","volume":"158","author":"U Ladabaum","year":"2020","unstructured":"Ladabaum U, Dominitz JA, Kahi C, Schoen RE (2020) Strategies for colorectal cancer screening. Gastroenterology 158:418\u2013432. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.043","journal-title":"Gastroenterology"},{"key":"1570_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cdtm.2018.08.004","volume":"4","author":"D Li","year":"2018","unstructured":"Li D (2018) Recent advances in colorectal cancer screening. Chronic Dis Transl Med 4:139. https:\/\/doi.org\/10.1016\/j.cdtm.2018.08.004","journal-title":"Chronic Dis Transl Med"},{"key":"1570_CR8","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1158\/1055-9965.EPI-08-0095","volume":"17","author":"DM Boudreau","year":"2008","unstructured":"Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R, Mandelson MT (2008) Cardiovascular medication use and risk for colorectal cancer. Cancer Epidemiol Biomark Prev 17:3076\u20133080. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-0095","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"1570_CR9","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2011.35.1908","volume":"29","author":"C-H Chang","year":"2011","unstructured":"Chang C-H, Lin J-W, Wu L-C, Lai M-S (2011) Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 29:3001\u20133007. https:\/\/doi.org\/10.1200\/JCO.2011.35.1908","journal-title":"J Clin Oncol"},{"key":"1570_CR10","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001097","author":"P-Y Chang","year":"2015","unstructured":"Chang P-Y, Huang W-Y, Lin C-L et al (2015) Propranolol reduces cancer risk: a population-based cohort study. Medicine. https:\/\/doi.org\/10.1097\/MD.0000000000001097","journal-title":"Medicine"},{"key":"1570_CR11","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1161\/HYPERTENSIONAHA.120.15317","volume":"76","author":"KS Cheung","year":"2020","unstructured":"Cheung KS, Chan EW, Seto WK, Wong IC, Leung WK (2020) ACE (angiotensin-converting enzyme) inhibitors\/angiotensin receptor blockers are associated with lower colorectal cancer risk: A territory-wide study with propensity score analysis. Hypertension 76:968\u2013975. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.15317","journal-title":"Hypertension"},{"key":"1570_CR12","unstructured":"Deshpande G (2013) Association between cardiovascular drugs and colon cancer. Dissertation, University of Maryland"},{"key":"1570_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ypmed.2017.01.011","volume":"99","author":"T Dierssen-Sotos","year":"2017","unstructured":"Dierssen-Sotos T, G\u00f3mez-Acebo I, Palazuelos C et al (2017) Relationship between drugs affecting the renin-angiotensin system and colorectal cancer: the MCC-Spain study. Prev Med 99:178\u2013184. https:\/\/doi.org\/10.1016\/j.ypmed.2017.01.011","journal-title":"Prev Med"},{"key":"1570_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","volume":"74","author":"J Hallas","year":"2012","unstructured":"Hallas J, Christensen R, Andersen M, Friis S, Bjerrum L (2012) Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: a population-based case-control study. Br J Clin Pharmacol 74:180\u2013188. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04170.x","journal-title":"Br J Clin Pharmacol"},{"key":"1570_CR15","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1002\/cncr.26727","volume":"118","author":"L Jansen","year":"2012","unstructured":"Jansen L, Below J, Chang-Claude J, Brenner H, Hoffmeister M (2012) Beta blocker use and colorectal cancer risk: Population-based case-control study. Cancer 118:3911\u20133919. https:\/\/doi.org\/10.1002\/cncr.26727","journal-title":"Cancer"},{"key":"1570_CR16","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/bcp.13152","volume":"83","author":"IS Mackenzie","year":"2017","unstructured":"Mackenzie IS, Morant SV, Wei L, Thompson AM, MacDonald TM (2017) Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. Br J Clin Pharmacol 83:653\u2013663. https:\/\/doi.org\/10.1111\/bcp.13152","journal-title":"Br J Clin Pharmacol"},{"key":"1570_CR17","doi-asserted-by":"publisher","first-page":"djt374","DOI":"10.1093\/jnci\/djt374","volume":"106","author":"GA Makar","year":"2014","unstructured":"Makar GA, Holmes JH, Yang Y-X (2014) Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst 106:djt374. https:\/\/doi.org\/10.1093\/jnci\/djt374","journal-title":"J Natl Cancer Inst"},{"key":"1570_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0002-9343(00)00674-4","volume":"110","author":"A Tenenbaum","year":"2001","unstructured":"Tenenbaum A, Motro M, Jonas M et al (2001) Is diuretic therapy associated with an increased risk of colon cancer? Am J Med 110:143\u2013145. https:\/\/doi.org\/10.1016\/S0002-9343(00)00674-4","journal-title":"Am J Med"},{"key":"1570_CR19","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cncr.23215","volume":"112","author":"R Van Der Knaap","year":"2008","unstructured":"Van Der Knaap R, Siemes C, Coebergh JWW, van Duijn CM, Hofman A, Stricker BHC (2008) Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion\/deletion polymorphism, and cancer: the rotterdam study. Cancer 112:748\u2013757. https:\/\/doi.org\/10.1002\/cncr.23215","journal-title":"Cancer"},{"key":"1570_CR20","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","volume":"167","author":"K-L Wang","year":"2013","unstructured":"Wang K-L, Liu C-J, Chao T-F et al (2013) Long-term use of angiotensin II receptor blockers and risk of cancer: a population-based cohort analysis. Int J Cardiol 167:2162\u20132166. https:\/\/doi.org\/10.1016\/j.ijcard.2012.05.096","journal-title":"Int J Cardiol"},{"key":"1570_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/1470320319895646","author":"X Chen","year":"2020","unstructured":"Chen X, Yi C-h, Ya K-g (2020) Renin\u2013angiotensin system inhibitor use and colorectal cancer risk and mortality: a dose\u2013response meta analysis. J Renin Angiotensin Aldosterone Syst. https:\/\/doi.org\/10.1177\/1470320319895646","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"1570_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10552-015-0617-1","volume":"26","author":"Y-N Dai","year":"2015","unstructured":"Dai Y-N, Wang J-H, Zhu J-Z, Lin J-Q, Yu C-H, Li Y-M (2015) Angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers therapy and colorectal cancer: a systematic review and meta-analysis. Cancer Causes Control 26:1245\u20131255. https:\/\/doi.org\/10.1007\/s10552-015-0617-1","journal-title":"Cancer Causes Control"},{"key":"1570_CR23","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thomas J, Chandler J et al (2019) Cochrane handbook for systematic reviews of interventions: John Wiley & Sons","DOI":"10.1002\/9781119536604"},{"key":"1570_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003583","volume":"18","author":"M Page","year":"2021","unstructured":"Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med 18:e1003583. https:\/\/doi.org\/10.1371\/journal.pmed.1003583","journal-title":"PLoS Med"},{"key":"1570_CR25","doi-asserted-by":"crossref","unstructured":"Chien PF, Khan KS, Siassakos D (2012) Registration of systematic reviews: PROSPERO. Wiley Online Library","DOI":"10.1111\/j.1471-0528.2011.03242.x"},{"key":"1570_CR26","first-page":"727","volume":"18","author":"GA Wells","year":"2014","unstructured":"Wells GA, Shea B, O\u2019Connell D et al (2014) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Appl Eng Agric 18:727\u2013734","journal-title":"Appl Eng Agric"},{"key":"1570_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558. https:\/\/doi.org\/10.1002\/sim.1186","journal-title":"Stat Med"},{"key":"1570_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"1570_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177\u2013188. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2","journal-title":"Control Clin Trials"},{"key":"1570_CR30","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326:219. https:\/\/doi.org\/10.1136\/bmj.326.7382.219","journal-title":"BMJ"},{"key":"1570_CR31","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"1570_CR32","unstructured":"The Cochrane Collaboration (2014) Review Manager (RevMan). The Nordic Cochrane Centre. https:\/\/www.R-project.org. Accessed 8 Sep 2021"},{"key":"1570_CR33","unstructured":"Team RC (2018) R: A language and environment for statistical computing. R Foundation for Statistical Computing. https:\/\/www.R-project.org. Accessed 8 Sep 2021"},{"key":"1570_CR34","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.ijcard.2014.11.031","volume":"177","author":"CA D\u00e9zsi","year":"2014","unstructured":"D\u00e9zsi CA (2014) A review of clinical studies on angiotensin II receptor blockers and risk of cancer. Int J Cardiol 177:748\u2013753. https:\/\/doi.org\/10.1016\/j.ijcard.2014.11.031","journal-title":"Int J Cardiol"},{"key":"1570_CR35","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/216762a0","volume":"216","author":"K Ng","year":"1967","unstructured":"Ng K, Vane J (1967) Conversion of angiotensin I to angiotensin II. Nature 216:762\u2013766. https:\/\/doi.org\/10.1038\/216762a0","journal-title":"Nature"},{"key":"1570_CR36","doi-asserted-by":"publisher","first-page":"R205","DOI":"10.1152\/ajpregu.00544.2012","volume":"305","author":"D Okwan-Duodu","year":"2013","unstructured":"Okwan-Duodu D, Landry J, Shen XZ, Diaz R (2013) Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis. Am J Physiol Regul Integr Comp Physiol 305:R205\u2013R215. https:\/\/doi.org\/10.1152\/ajpregu.00544.2012","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"1570_CR37","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/HCO.0b013e328353bc4f","volume":"27","author":"A Singh","year":"2012","unstructured":"Singh A, Bangalore S (2012) Which, if any, antihypertensive agents cause cancer? Curr Opin Cardiol 27:374\u2013380. https:\/\/doi.org\/10.1097\/HCO.0b013e328353bc4f","journal-title":"Curr Opin Cardiol"},{"key":"1570_CR38","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2147\/VHRM.S13552","volume":"7","author":"G Wuerzner","year":"2011","unstructured":"Wuerzner G, Burnier M, Waeber B (2011) Critical review of cancer risk associated with angiotensin receptor blocker therapy. Vasc Health Risk Manag 7:741. https:\/\/doi.org\/10.2147\/VHRM.S13552","journal-title":"Vasc Health Risk Manag"},{"key":"1570_CR39","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/ijc.25234","volume":"127","author":"N Clere","year":"2010","unstructured":"Clere N, Corre I, Faure S et al (2010) Deficiency or blockade of angiotensin II type 2 receptor delays tumorigenesis by inhibiting malignant cell proliferation and angiogenesis. Int J Cancer 127:2279\u20132291. https:\/\/doi.org\/10.1002\/ijc.25234","journal-title":"Int J Cancer"},{"key":"1570_CR40","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1096\/fj.03-0129com","volume":"17","author":"T Walther","year":"2003","unstructured":"Walther T, Menrad A, Orzechowski H-D, Siemeister G, Paul M, Schirner M (2003) Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 17:2061\u20132067. https:\/\/doi.org\/10.1096\/fj.03-0129com","journal-title":"FASEB J"},{"key":"1570_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-017-0500-2","volume":"18","author":"Y Deng","year":"2017","unstructured":"Deng Y (2017) Rectal cancer in Asian vs. Western countries: why the variation in incidence? Curr Treat Options Oncol 18:1\u20138. https:\/\/doi.org\/10.1007\/s11864-017-0500-2","journal-title":"Curr Treat Options Oncol"},{"key":"1570_CR42","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub5","author":"CS Wiysonge","year":"2017","unstructured":"Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH (2017) Beta-blockers for hypertension. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD002003.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"1570_CR43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/MD.0000000000016047","volume":"98","author":"M-S Kim","year":"2019","unstructured":"Kim M-S, Do Han K, Kwon SY (2019) Pre-diagnostic beta-blocker use and head-and neck cancer risk: A nationwide population-based case-control study. Medicine 98:24. https:\/\/doi.org\/10.1097\/MD.0000000000016047","journal-title":"Medicine"},{"key":"1570_CR44","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1161\/01.HYP.29.5.1091","volume":"29","author":"JH Olsen","year":"1997","unstructured":"Olsen JH, S\u00f8rensen HT, Friis S et al (1997) Cancer risk in users of calcium channel blockers. Hypertension 29:1091\u20131094. https:\/\/doi.org\/10.1161\/01.HYP.29.5.1091","journal-title":"Hypertension"},{"key":"1570_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-00914","volume":"6","author":"L Grimaldi-Bensouda","year":"2016","unstructured":"Grimaldi-Bensouda L, Klungel O, Kurz X et al (2016) Calcium channel blockers and cancer: a risk analysis using the UK Clinical Practice Research Datalink (CPRD). BMJ Open 6:e009147. https:\/\/doi.org\/10.1136\/bmjopen-2015-00914","journal-title":"BMJ Open"},{"key":"1570_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF01142195","volume":"2","author":"AC Durham","year":"1982","unstructured":"Durham AC, Walton JM (1982) Calcium ions and the control of proliferation in normal and cancer cells. Biosci Rep 2:15\u201330. https:\/\/doi.org\/10.1007\/BF01142195","journal-title":"Biosci Rep"},{"key":"1570_CR47","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1096\/fasebj.9.2.7781924","volume":"9","author":"BF Trump","year":"1995","unstructured":"Trump BF, Berezesky IK (1995) Calcium-mediated cell injury and cell death. FASEB J 9:219\u2013228. https:\/\/doi.org\/10.1096\/fasebj.9.2.7781924","journal-title":"FASEB J"},{"key":"1570_CR48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/1040-842(94)00124-C","volume":"18","author":"SJ Martin","year":"1995","unstructured":"Martin SJ, Green DR (1995) Apoptosis and cancer: the failure of controls on cell death and cell survival. Crit Rev Oncol Hematol 18:137\u2013153. https:\/\/doi.org\/10.1016\/1040-842(94)00124-C","journal-title":"Crit Rev Oncol Hematol"},{"key":"1570_CR49","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0140-6736(05)64695-8","volume":"348","author":"L Hardell","year":"1996","unstructured":"Hardell L, Axelson O, Fredrikson M (1996) Antihypertensive drugs and risk of malignant diseases. Lancet 348:542. https:\/\/doi.org\/10.1016\/S0140-6736(05)64695-8","journal-title":"Lancet"},{"key":"1570_CR50","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/sj.jhh.1001192","volume":"15","author":"A Tenenbaum","year":"2001","unstructured":"Tenenbaum A, Grossman E, Fisman E et al (2001) Long-term diuretic therapy in patients with coronary disease: increased colon cancer-related mortality over a 5-year follow-up. J Hum Hypertens 15:373\u2013379. https:\/\/doi.org\/10.1038\/sj.jhh.1001192","journal-title":"J Hum Hypertens"},{"key":"1570_CR51","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S1470-2045(21)00033-4","volume":"22","author":"E Copland","year":"2021","unstructured":"Copland E, Canoy D, Nazarzadeh M et al (2021) Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncol 22:558\u2013570. https:\/\/doi.org\/10.1016\/S1470-2045(21)00033-4","journal-title":"Lancet Oncol"},{"key":"1570_CR52","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/BF02234301","volume":"44","author":"EC Gonzalez","year":"2001","unstructured":"Gonzalez EC, Roetzheim RG, Ferrante JM, Campbell R (2001) Predictors of proximalvs. distal colorectal cancers. Dis Colon Rectum 44:251\u2013258. https:\/\/doi.org\/10.1007\/BF02234301","journal-title":"Dis Colon Rectum"},{"key":"1570_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e3953","author":"IJ Marshall","year":"2012","unstructured":"Marshall IJ, Wolfe CD, McKevitt C (2012) Lay perspectives on hypertension and drug adherence: systematic review of qualitative research. BMJ. https:\/\/doi.org\/10.1136\/bmj.e3953","journal-title":"BMJ"},{"key":"1570_CR54","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/fampra\/cmh202","volume":"21","author":"JJ Gascon","year":"2004","unstructured":"Gascon JJ, S\u00e1nchez-Ortu\u00f1o M, Llor B, Skidmore D, Saturno PJ (2004) Why hypertensive patients do not comply with the treatment: results from a qualitative study. Fam Pract 21:125\u2013130. https:\/\/doi.org\/10.1093\/fampra\/cmh202","journal-title":"Fam Pract"}],"container-title":["Cancer Causes & Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-022-01570-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10552-022-01570-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-022-01570-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T08:19:28Z","timestamp":1652084368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10552-022-01570-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1570"],"URL":"https:\/\/doi.org\/10.1007\/s10552-022-01570-1","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"type":"print","value":"0957-5243"},{"type":"electronic","value":"1573-7225"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"11 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rachel A. Murphy has received consulting fees from Pharmavite LLC for projects related outside of the submitted work. Other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}